|
The top-line for March 2016 quarter inclined by 11% to Rs 613.80 crore. Both the feminine care and health care business posted double digit sales growth in competitive environment behind superior value propositions and the strength of product portfolio. OPM has declined by 40 bps to 21.7%. The net profit has increased by 12% to Rs 97.30 crore due to rise in other income and fall in interest cost.
Performance for the quarter ended March 2016
The top-line inclined by 11% to Rs 613.80 crore. Both the feminine care and health care business posted double digit sales growth in competitive environment behind superior value propositions and the strength of product portfolio.
OPM has declined by 40 bps to 21.7% due to increase in raw material cost by 170 bps to 24.4%, ASP cost by 270 bps to 15.2% and other expenses by 160 bps to 16.4% of adjusted net sales. The operating profit increased by 8% to Rs 133.23 crore.
Other income increased by 33% to Rs 23.63 crore. Interest cost decreased by 94% to Rs 0.24 crore. Depreciation has decreased by 2% to Rs 12.38 crore. PBT has increased by 16% to Rs 144.24 crore.
The tax outgo inclined by 25% to Rs 46.94 crore. The effective tax rate inclined from 30.2% to 32.5%. The net profit has increased by 12% to Rs 97.30 crore due to rise in other income and fall in interest cost.
Performance for nine months ended March 2016
The top-line inclined by 8% to Rs 1926.06 crore. OPM has inclined by 460 bps to 23.2% due to fall in raw material cost and ASP. The operating profit increased by 35% to Rs 446.07 crore.
Other income increased by 17% to Rs 65.43 crore. Interest cost decreased by 32% to Rs 3.69 crore. Depreciation was flat at Rs 39.28 crore. PBT has increased by 37% to Rs 468.53 crore.
The tax outgo inclined by 51% to Rs 154.75 crore. The effective tax rate increased from 30% to 33%. The net profit has increased by 31% to Rs 313.78 crore.
Promoters holding and valuation
The promoters hold 70.64% stake in the company
The shares of the company are trading around Rs 6299.40 at BSE.
|